发明名称 Use of Dextran Sulfate
摘要 A method of inhibiting Instant Blood-Mediated Inflammatory Reaction (IBMIR) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient. The dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average molecular weight of less than 20,000 Da and an average sulphur content in a range of 10 to 25%, and the inhibition comprises administering said therapeutically effective amount of said dextran sulfate, or said pharmaceutically acceptable salt thereof, resulting in a concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, in the blood of said patient of less than 5 mg/ml.
申请公布号 US2014094435(A1) 申请公布日期 2014.04.03
申请号 US201314099518 申请日期 2013.12.06
申请人 TX MEDIC AB 发明人 NILSSON BO;KORSGREN OLLE
分类号 A61K31/721;A61K;A61P37/06 主分类号 A61K31/721
代理机构 代理人
主权项
地址